Overview

• Peripheral nerve repair firm's preliminary Q4 revenue rose 21.3%, beating analyst expectations

• Company's revenue growth driven by strong product performance and strategic execution

• FDA approval of Avance impacted gross margin with one-time costs

Result Drivers

• PRODUCT PERFORMANCE - Strong performance across AxoGen's product portfolio drove Q4 revenue growth

• STRATEGIC EXECUTION - Improved execution of commercial strategy targeting high-potential accounts contributed to revenue increase

• FDA APPROVAL IMPACT - FDA approval of Avance led to one-time costs affecting gross margin

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for AxoGen Inc is $36.50, about 8.9% above its January 9 closing price of $33.51

• The stock recently traded at 69 times the next 12-month earnings vs. a P/E of 42 three months ago

Press Release: ID:nGNX2Ybtnd

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)